司徒惠康(Huey-Kang Sytwu)

Huey-Kang

Occupation

國家衛生研究院 副院長 (Distinguished investigator and vice president of National Health Research Institutes)

司徒惠康博士於 1987 年取得國防醫學中心醫學博士學位,並於 1997 年於美國史丹佛大學獲得博士學位,目前為國家衛生研究院的特聘研究員暨副院長。他的研究專注於胰島素依賴型糖尿病(IDDM)自體免疫之分子機制,並以非肥胖糖尿病(NOD)小鼠為模式,以基因工程(gene manipulation)來預防疾病的進程。 IDDM 是由朗格罕氏胰島中產生胰島素的 β 細胞逐步因自體免疫破壞引起的,遺傳易感性和環境因素均影響其病程。NOD 小鼠為廣泛用於剖析 IDDM 免疫病理機制的研究,適用於開發預防或/及治療策略的動物模型,它是一種近親品系小鼠,能自發性的發展類似於人類 IDDM 的自身免疫性糖尿病。為了剖析I型糖尿病的免疫致病機制並開發針對這種自身免疫性疾病的潛在治療策略,司徒博士及其同僚已經建立了 30 多株轉殖基因小鼠,包括基因剔除(knockout)與基因表現抑制(knockdown)的 NOD 小鼠。 藉由充分利用這些獨特的小鼠品系進行定量與定性地分析研究了自身免疫性糖尿病的免疫致病機制,並為開發基於基因修飾的胰島的新型免疫療法提供有價值的訊息。

Dr. Huey-Kang Sytwu received his MD degree from National Defense Medical Center, Taipei, Taiwan in 1987 and PhD degree from Stanford University, USA in 1997. He is currently a distinguished investigator and vice president of National Health Research Institutes. His laboratory focuses on the molecular dissection of autoimmune mechanisms of insulin-dependent diabetes mellitus (IDDM) and the genetic manipulation in preventing the pathogenic process in non-obese diabetic (NOD) mice. IDDM is caused by a progressive autoimmune destruction of the insulin-producing β cells in the pancreatic islets of Langerhans. Both genetic predisposition and environmental factors contribute to its pathogenesis. A widely used animal model for dissecting immunopathological mechanisms in IDDM and for developing preventive and/or therapeutic strategies is the NOD mouse, an inbred strain that spontaneously develops autoimmune diabetes resembling human IDDM. To dissect the immunopathogenic mechanisms of type I diabetes and to develop potential therapeutic strategy for this autoimmune disease, Dr. Sytwu and his labmates have already established more than 30 novel transgenic, knockout and knockdown NOD mice in the Sytwu laboratory. Making full use of these unique mouse strains, Dr. Sytwu and his colleagues are quantitatively and qualitatively investigating the immunopathogenic mechanisms of autoimmune diabetes and provide valuable information for the development of novel genetically modified islets-based immunotherapies.